Research programme: PRL-3-targeting agents - Sanofi Genzyme

Drug Profile

Research programme: PRL-3-targeting agents - Sanofi Genzyme

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Class Small molecules
  • Mechanism of Action Phosphoric monoester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer metastases

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 23 Apr 2004 This programme is still in active development - 95th Annual Meeting of the American Association for Cancer Research (AACR-2004)
  • 02 Apr 2002 Preclinical trials in Cancer metastases in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top